- Home
- AVTX vs BMEA Comparison
AVTX vs BMEA Comparison
Compare AVTX & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVTX
- BMEA
- Stock Information
- Founded
- AVTX 2011
- BMEA 2017
- Country
- AVTX United States
- BMEA United States
- Employees
- AVTX N/A
- BMEA N/A
- Industry
- AVTX Biotechnology: Pharmaceutical Preparations
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- AVTX Health Care
- BMEA Health Care
- Exchange
- AVTX Nasdaq
- BMEA Nasdaq
- Market Cap
- AVTX 57.4M
- BMEA 65.8M
- IPO Year
- AVTX 2015
- BMEA 2021
- Fundamental
- Price
- AVTX $4.73
- BMEA $1.81
- Analyst Decision
- AVTX Strong Buy
- BMEA Strong Buy
- Analyst Count
- AVTX 7
- BMEA 10
- Target Price
- AVTX $31.00
- BMEA $22.30
- AVG Volume (30 Days)
- AVTX 89.2K
- BMEA 5.2M
- Earning Date
- AVTX 08-11-2025
- BMEA 07-30-2025
- Dividend Yield
- AVTX N/A
- BMEA N/A
- EPS Growth
- AVTX N/A
- BMEA N/A
- EPS
- AVTX N/A
- BMEA N/A
- Revenue
- AVTX $441,000.00
- BMEA N/A
- Revenue This Year
- AVTX N/A
- BMEA N/A
- Revenue Next Year
- AVTX N/A
- BMEA N/A
- P/E Ratio
- AVTX $0.69
- BMEA N/A
- Revenue Growth
- AVTX N/A
- BMEA N/A
- 52 Week Low
- AVTX $3.39
- BMEA $1.29
- 52 Week High
- AVTX $16.00
- BMEA $13.07
- Technical
- Relative Strength Index (RSI)
- AVTX 57.87
- BMEA 44.35
- Support Level
- AVTX $4.46
- BMEA $2.24
- Resistance Level
- AVTX $4.90
- BMEA $3.08
- Average True Range (ATR)
- AVTX 0.37
- BMEA 0.40
- MACD
- AVTX 0.09
- BMEA -0.03
- Stochastic Oscillator
- AVTX 88.61
- BMEA 25.07
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.